Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0043-106017 | DOI Listing |
BMC Cardiovasc Disord
December 2024
Beijing Anzhen Hospital, Capital Medical University, Anzhen road No.1, Beijing, China.
Background: Few studies investigated the implications of post-PCI QFR and post-PCI ΔQFR (absolute increase of QFR) in de novo lesions of small coronary disease after drug-coated balloon (DCB).
Objectives: We sought to investigate the prognostic implications of post-PCI QFR and post-PCI ΔQFR in patients who received DCB only.
Methods: Patients were divided according to the optimal cutoff value of the post-PCI QFR and the post-PCI ΔQFR.
J Vasc Interv Radiol
December 2024
Vascular and Interventional Radiology Translational Research Lab, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Purpose: Describe the immunohistologic changes in arteriovenous fistula (AVF) stenosis treated using plain old balloon angioplasty (POBA) versus paclitaxel drug-coated balloons (DCB) MATERIALS AND METHODS: Castrated male Yorkshire pigs (n = 12) 4-5 months old had chronic kidney disease (CKD) induced with renal artery embolization. Twenty-eight days later, a side-to-end anastomosis was created between the left common carotid artery to ipsilateral external jugular vein. Four weeks later, a juxta anastomotic stenosis was treated with balloon angioplasty (PTA) or DCB and animals euthanized at 4 [POBA (n=6)] and 42 days [POBA (n=3) or DCB (n=3)] for histomorphometric analysis with immunohistochemical staining for CD-68 (macrophages), FSP-1 (fibroblasts), α-SMA (smooth muscle cells, SMCs), CD-31 (endothelial), proliferation (Ki-67), and apoptosis (TUNEL).
View Article and Find Full Text PDFJ Endovasc Ther
December 2024
Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Azienda Ospedaliera Universitaria Policlinico "G. Martino," Messina, Italy.
Introduction: Initial surgical revascularization has a recognized primary role in patients with critical limb-threatening ischemia with a high-quality great saphenous vein for conduit. However, approximately one-third of lower extremity vein grafts develop lesions threatening graft patency. Traditional treatments have limitations, highlighting the need for innovative solutions.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
December 2024
Department of Cardiology, Central Japan International Medical Center, Minokamo, Japan.
Background: The impact of below-the-knee (BK) runoff after drug-coated balloon (DCB) treatment in femoropopliteal (FP) lesions has not been well investigated.
Methods: This retrospective multicenter observational study enrolled 291 consecutive patients with lower extremity artery disease who underwent endovascular therapy with DCBs for FP lesions between January 2018 and December 2021. Patients were classified into four groups based on the BK runoff.
Catheter Cardiovasc Interv
December 2024
DCB Academy, Milano, Italy.
Background: Drug-coated balloons (DCB) are emerging as an alternative to permanent implants for managing de novo coronary artery disease, particularly in small vessels (SVD). This sub-analysis of the PICCOLETO II study aimed to compare the performance of DCB and DES in terms of Murray's law-based quantitative flow ratio (μFR) changes between baseline, post-percutaneous coronary intervention (PCI), and follow-up.
Methods: Patients with a clinical indication for PCI were assigned to receive either Xience DES or Elutax SV/Emperor DCB.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!